Detects expression of tropomyosin receptor kinase A, B, and C proteins arising from the NTRK 1, 2, and 3 genes, respectively. NTRK gene rearrangements occur in many different tumor types, often at low frequency, including lung non-small cell carcinomas, colorectal and other GI-related adenocarcinomas, breast carcinomas, melanoma, renal cell carcinomas, and adult brain tumors. IHC screening is not recommended in neuroendocrine tumors, GISTs, gliomas, or adult sarcomas, as these tissues so positive staining in the absence of an NTRK translocation. Instead, molecular testing (i.e. NGS or FISH) for an NTRK gene fusion is recommended to confirm the presence of an NTRK gene fusion. Patients having a tumor harboring an NTRK gene fusion may be responsive to NTRK inhibitor therapy.
A formalin-fixed, paraffin-embedded (FFPE) tissue block is preferred specimen typeorOne (1) unbaked, unstained slide for H&E staining (required) and two to three (2-3) positively charged unstained slides (all cut at 4-5 microns) for each test/antibody orderedBlock and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.